

February 5, 2025

To whom it may concern:

Company name:	TAIYO HOLDINGS CO., LTD.				
Representative:	Eiji Sato, President and CEO				
	(Code: 4626, Listed on Prime Market of				
	Tokyo Stock Exchange)				
Inquiries:	Sayaka Tomioka, Managing Executive				
	Officer, CFO				
	Tel: +81-3-5953-5200 (main line)				

## Notice of Revised Full-year Earnings Forecasts for the Fiscal Year Ended March 31, 2025

TAIYO HOLDINGS CO., LTD. hereby announces the revision of the full-year (from April 1, 2024, to March 31, 2025) consolidated earnings forecasts for the fiscal year ended March 31, 2025 disclosed on November 6, 2024. The revised forecasts were approved at the Board of Directors meeting held on February 5, 2025.

1. Revised consolidated earnings forecast for the fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Basic earnings per share
	Millions of	Millions of	Millions of	Millions of	
Previously announced forecast (A)	yen 117,700	yen 21,700	yen 21,100	yen 14,500	Yen 258.76
Revised forecast (B)	118,600	22,300	21,700	14,900	267.00
Change (B-A)	900	600	600	400	
Change (%)	0.8	2.8	2.8	2.8	
For reference: Results for the fiscal year ended March 31, 2024	104,775	18,203	17,310	8,654	154.89

## 2. Reasons for revision

The performance of the Electronics business in the third quarter outperformed the forecast due to weaker than expected yen and higher than expected demand for rigid board materials.

In light of these, we therefore revised the consolidated earnings forecasts, leaving the earnings forecast for the fourth quarter at the level announced on November 6, 2024 and replacing the Electronics business earnings forecast for the third quarter with the actual results. The forecasts for the "Medical and Pharmaceuticals" and "ICT and Sustainability" businesses have not been revised.

## 3. Dividend forecast

There has been no change in the dividend forecast announced on May 1, 2024.

## For reference:

Segment forecasts for net sales and operating income

	Segment	Fiscal	Fiscal year ended March 31, 2024		
		Previously announced forecast (A)	Revised forecast (B)	Change (B-A)	Previous fiscal year results
Net sales	Consolidated	117,700	118,600	900	104,775
	Electronics	80,300	81,200	900	71,415
	Medical and Pharmaceuticals	32,500	32,500	0	29,269
Operating income	Consolidated	21,700	22,300	600	18,203
	Electronics	20,800	21,400	600	16,456
	Medical and Pharmaceuticals	2,200	2,200	0	3,248

\* The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. The Company makes no promise regarding achievement of any content in the forward-looking statements. Actual business and other results may differ substantially due to various factors.